Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 8Recruiting 4Unknown 3Terminated 2Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other hematologic neoplasm 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 87Cyclophosphamide 67Capecitabine 67Paclitaxel 64Docetaxel 58Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 41Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 19atezolizumab 18pertuzumab 17Everolimus 17130-nm albumin-bound paclitaxel 17Epirubicin 16palbociclib 15Magnetic Resonance Spectroscopy 15eribulin 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Anthracyclines × Breast × Clear all
NCT02561832 2019-02-20

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

AstraZeneca

Phase 1 Terminated
15 enrolled 8 charts
Breast

Breast Neoplasms

NCT00912444 2016-11-22

NATT

Shanghai Jiao Tong University School of Medicine

Phase 3 Terminated
102 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡